CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.
An international childhood leukemia trial integrates targeted therapies for different genetic subtypes, aiming to move beyond one-size-fits-all chemotherapy.
CHIP-AML22 is a complex, international pediatric AML randomized trial (NOPHO-DB-SHIP consortium, 49 institutions) incorporating GO randomization plus quizartinib-targeted therapy for eligible subgroups, addressing the need for improved precision therapy in de novo pediatric AML. This protocol publication registers the trial framework for the field.
What the study was
- Study design
- Complex randomized clinical trial protocol
- Population
- De novo pediatric AML patients enrolled in the NOPHO-DB-SHIP international consortium
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Trials
Why it surfaced
International pediatric AML trial protocol representing best-practice collaborative science; pediatric AML remains a high-unmet-need, high-risk population. Protocol only — no results.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.